These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37354147)
1. Black Women and Transthyretin Amyloidosis: Insights From the Women's Health Initiative. Falk RH; Kattan CG JACC Heart Fail; 2023 Sep; 11(9):1200-1202. PubMed ID: 37354147 [No Abstract] [Full Text] [Related]
2. Transthyretin Cardiac Amyloidosis in Black Americans. Shah KB; Mankad AK; Castano A; Akinboboye OO; Duncan PB; Fergus IV; Maurer MS Circ Heart Fail; 2016 Jun; 9(6):e002558. PubMed ID: 27188913 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and Outcomes of p.Val142Ile Chandrashekar P; Alhuneafat L; Mannello M; Al-Rashdan L; Kim MM; Dungu J; Alexander K; Masri A Circ Genom Precis Med; 2021 Oct; 14(5):e003356. PubMed ID: 34461737 [TBL] [Abstract][Full Text] [Related]
4. Understanding Changes in Functional Capacity After TTR Stabilization in Patients With Transthyretin Cardiac Amyloidosis. Cuddy SAM Circ Heart Fail; 2022 Jul; 15(7):e009387. PubMed ID: 35766044 [No Abstract] [Full Text] [Related]
5. Cardiac transthyretin/leukocyte chemotactic factor (LECT) 2 double amyloidosis in a patient suffering from heart failure. Greulich S; Mahrholdt H; Casadonte R; Steinmüller-Magin L; Latus J; Blessing F; Kriegsmann J; Bekeredjian R; Gawaz M; Klingel K Clin Res Cardiol; 2023 Mar; 112(3):444-449. PubMed ID: 35925392 [No Abstract] [Full Text] [Related]
6. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy. Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650 [TBL] [Abstract][Full Text] [Related]
7. Cardiac involvement in a large cohort of patients with Val30Met transthyretin amyloidosis from Majorca focus. Ripoll-Vera T; Alvarez J; Buades J; Cisneros E; Gomez Y; Melia C; Ferrer A; Losada I; Gonzalez J; Uson M; Figuerola A Amyloid; 2019; 26(sup1):15-16. PubMed ID: 31343338 [No Abstract] [Full Text] [Related]
9. A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. Huda A; Castaño A; Niyogi A; Schumacher J; Stewart M; Bruno M; Hu M; Ahmad FS; Deo RC; Shah SJ Nat Commun; 2021 May; 12(1):2725. PubMed ID: 33976166 [TBL] [Abstract][Full Text] [Related]
10. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Maurer MS; Hanna M; Grogan M; Dispenzieri A; Witteles R; Drachman B; Judge DP; Lenihan DJ; Gottlieb SS; Shah SJ; Steidley DE; Ventura H; Murali S; Silver MA; Jacoby D; Fedson S; Hummel SL; Kristen AV; Damy T; Planté-Bordeneuve V; Coelho T; Mundayat R; Suhr OB; Waddington Cruz M; Rapezzi C; J Am Coll Cardiol; 2016 Jul; 68(2):161-72. PubMed ID: 27386769 [TBL] [Abstract][Full Text] [Related]
11. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Rubin J; Maurer MS Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086 [TBL] [Abstract][Full Text] [Related]